Emergent BioSolutions Inc. EBS
Set alert
6.96 USD +0.52 +8.07%
As of Nov 3, 10:43 AM ET
5.51 Day range 7.22
4.36 52-week range 14.06
- YTD
- -43.69%
- 1 year
- -33.65%
- Open
- 5.51
- Prev close
- 6.44
- Mkt cap
- 356.85M
- Vol
- 963.92K
- Avg vol
- 1.24M
- EPS
- -3.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.51
- High
- 7.22
- Forward P/E
- 2.73
- Beta
- 1.57
- Short ratio
- 4.54
- Inst. own
- 60.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.27
- 200-d avg
- 7.13
- 1y target
- 12.00
5D chart
Signals (64)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Nov 3, 9:55 AM | 49 minutes ago |
| SMA: Bullish | Nov 3, 9:35 AM | 1 hour ago |
| RSI: Overbought | Nov 3, 9:35 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 3:55 PM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 3:55 PM | 18 hours ago |
| RSI: Oversold | Nov 2, 3:10 PM | 19 hours ago |
| RSI: Oversold | Nov 2, 2:45 PM | 19 hours ago |
| RSI: Oversold | Nov 2, 1:55 PM | 20 hours ago |
| RSI: Oversold | Nov 2, 1:35 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 12:20 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 11:55 AM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 10:35 AM | 1 day ago |
| RSI: Oversold | Nov 2, 10:05 AM | 1 day ago |
| RSI: Oversold | Nov 2, 9:45 AM | 1 day ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 1 day ago |
| RSI: Oversold | Nov 2, 9:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 3 days ago |
Newest 20 of 64.
Analyst view
Consensus: buy
Buy
Price target (mean) 12.00
Ratings (0m) 2 1 buy · 0 hold · 1 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell1
Recommendation trend
- This month 2
- 1 month ago 2
- 2 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.64 | -0.64 – -0.64 | -0.77 | +16.9% | 248.00M | -10.3% | 1 |
| Next quarter | 1.14 | 1.14 – 1.14 | 0.59 | +93.2% | 0 | 0.0% | 1 |
| Current year | -0.81308 | -1.00 – -0.62615 | -6.23 | +87.0% | 1.10B | +4.6% | 2 |
| Next year | 2.07 | 2.07 – 2.07 | -0.81308 | +354.0% | 1.09B | -0.2% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Benchmark | Maintained | Buy | Buy |
| Sep 13, 2024 | Rodman & Renshaw | Reiterated | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | Initiated | — | Buy |
| Aug 16, 2024 | Benchmark | Reiterated | Buy | Buy |
| Aug 9, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jul 3, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jul 2, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 24, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 21, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 20, 2024 | Benchmark | Maintained | Buy | Buy |
| Apr 11, 2024 | Benchmark | Reiterated | Buy | Buy |
| Mar 7, 2024 | Benchmark | Upgrade | Hold | Buy |
| Aug 29, 2023 | Benchmark | Downgrade | Buy | Hold |
| May 31, 2023 | Benchmark | Reiterated | Buy | Buy |
| May 19, 2023 | Benchmark | Reiterated | Buy | Buy |
| Apr 10, 2023 | Benchmark | Upgrade | Hold | Buy |
| Mar 17, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Nov 10, 2022 | Benchmark | Downgrade | Buy | Hold |
| Nov 9, 2022 | Chardan Capital | Maintained | — | Buy |
| Sep 12, 2022 | Cowen & Co. | Maintained | — | Market Perform |
| May 4, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Apr 29, 2022 | Chardan Capital | Maintained | — | Buy |
| Mar 10, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Nov 10, 2021 | Chardan Capital | Maintained | — | Buy |
| Nov 8, 2021 | Benchmark | Downgrade | Buy | Hold |
| May 5, 2021 | Argus Research | Downgrade | Buy | Hold |
| Apr 30, 2021 | Chardan Capital | Maintained | — | Buy |
| Apr 7, 2021 | Benchmark | Initiated | — | Buy |
| Feb 24, 2021 | Chardan Capital | Upgrade | Neutral | Buy |
| Feb 19, 2021 | Chardan Capital | Downgrade | Buy | Neutral |